Positive CHMP opinion paves way for Lundbeck's Vyepti in Europe

Lundbeck's migraine treatment Vyepti should be approved in Europe, according to the EMA's expert committee (CHMP), which evaluated the pharmaceutical company's marketing application during its November meeting.
Photo: Torben Klint/Ritzau Scanpix
Photo: Torben Klint/Ritzau Scanpix
BY ELIZABETH MØNSTED JOHANSEN, translated by daniel pedersen

Lundbeck is a huge step closer to realizing its launch of the migraine drug Vyepti on the European market.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading